Skip to Main Content

Paper Details

Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
Diabetes Obes Metab
1
2024
ALT, FIB-4, Finerenone, alanine, alanine transaminase, aspartate, aspartate aminotransferase, cardiovascular complications, cardiovascular death, chronic kidney disease, fibrosis, fibrosis-4, finerenone, gamma-glutamyl transferase, heart failure, hepatic steatosis, inflammation, kidney failure, liver steatosis, liver steatosis and fibrosis, non-fatal myocardial infarction, non-fatal stroke, patients, steatosis, type 2 diabetes
Author NameAffiliation
Stefan R BornsteinUniversity Study Center for Metabolic Diseases, Carl Gustav Carus University Clinic
Stefan R BornsteinKing's College London
Stefan R BornsteinGerman Center for Diabetes Research (DZD e.V.)
Stefan R BornsteinUniversity Hospital and Faculty of Medicine, Paul Langerhans Institute Dresden (PLID)
Gerasimos FilippatosNational and Kapodistrian University of Athens, Attikon University Hospital
  • 1 - 5

Datasets

Release 1.2